Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci179014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Zhenyu Dai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Natural Killer T-Cells, Pancreatic Neoplasms, Interleukin-15, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma cancer (PDAC) continues to pose a significant health burden, with a 5-year survival rate of only 10%. Prostate stem cell antigen (PSCA) is highly expressed on the surface of tumor cells of most PDAC patients, with minimum expression in most normal tissues. Here, we generated cryopreserved, off-the-shelf, allogeneic PSCA chimeric antigen receptor (CAR) invariant NKT (iNKT) cells using human peripheral blood mononuclear cells as a cell source. In multiple in vitro and in vivo PDAC models, freshly manufactured PSCA CAR_sIL-15 iNKT cells and frozen-thawed, off-the-shelf PSCA CAR_sIL-15 iNKT cells demonstrate comparable efficacies, and both show remarkable suppression of PSCA-positive and gemcitabine-resistant PDAC. Importantly, off-the-shelf cryopreserved PSCA CAR_sIL-15 iNKT cells show equivalent efficacy when compared with PSCA CAR T cells using the same PSCA CAR and in the same PDAC model; however, PSCA CAR_sIL-15 iNKT cells do not appear to induce systemic toxicity or graft-versus-host disease, thus allowing for multiple infusions to control recurrent disease. Collectively, our study suggests that PSCA CAR_sIL-15 iNKT cells merit clinical investigation for PDAC patients exhibiting positive PSCA expression. The therapy could be given as a single agent or in combination with established therapeutic modalities for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California, USA.
- Division of Hematology/Oncology, Department of Medicine, School of Medicine, and.
- The Clemons Family Center for Transformative Cancer Research, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
- Department of Computational and Quantitative Medicine.
- Division of Surgical Oncology, Department of Surgery, and.
- Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, California, USA.
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- Foundation for the National Institutes of Health
- California Institute for Regenerative Medicine
Zitieren
APA
Dai, Z., Zhu, Z., Li, Z., Tian, L., Teng, K. Y., Chen, H., Wang, L. S., Zhang, J., Melstrom, L., Caligiuri, M. A., & Yu, J. (2025). Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci179014
Vancouver
Dai Z, Zhu Z, Li Z, Tian L, Teng KY, Chen H, et al. Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. Journal of Clinical Investigation. 2025. doi:10.1172/jci179014
BibTeX
@article{Dai2025,
author = {Dai, Zhenyu and Zhu, Zheng and Li, Zhiyao and Tian, Lei and Teng, Kun-Yu and Chen, Hanyu and Wang, Li-Shu and Zhang, Jianying and Melstrom, Laleh and Caligiuri, Michael A and Yu, Jianhua},
title = {Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci179014}
}
EUVIMED